Luuk J.J. Scheres

ORCID: 0000-0001-5282-5520 · 4 papers in corpus
2024
Heavy menstrual bleeding on direct factor Xa inhibitors: the MEDEA randomized clinical trial.
Research and practice in thrombosis and haemostasis ·doi:10.1016/j.rpth.2024.102448
2024
Hormone-related thrombosis: duration of anticoagulation, risk of recurrence, and the role of hypercoagulability testing.
Hematology. American Society of Hematology. Education Program ·doi:10.1182/hematology.2024000593

Hormone-related venous thromboembolism (VTE) is common and entails scenarios in which VTE occurs during exposure to exogenous or endogenous female sex hormones, typically estrogen and progestogen. For the management of hormone-related VTE, …

letter 2022
Risk of venous thromboembolism in women with endometriosis
Thrombosis research ·doi:10.1016/j.thromres.2022.07.014
2018
Abnormal vaginal bleeding in women of reproductive age treated with edoxaban or warfarin for venous thromboembolism: a post hoc analysis of the Hokusai-VTE study.
BJOG : an international journal of obstetrics and gynaecology ·doi:10.1111/1471-0528.15388

ObjectiveTo investigate the characteristics and outcome of abnormal vaginal bleeding in women receiving edoxaban or warfarin for treatment of venous thromboembolism (VTE).Design and settingPost hoc analysis of the Hokusai-VTE study, a multi…